Anagram Therapeutics
Boston
About Anagram Therapeutics
Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $25.2M
- Funding stage: Private Equity
- Last round: Series Unknown (Oct 2020)
- Website: synspira.com
- Phone: (781) 235-3060
Industries & Categories
Biotechnology, Information Technology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anagram-therapeutics-53548 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.